Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk
Introduction Lung cancer is the world’s leading cause of cancer death. Low-dose computed tomography (LDCT) screening reduced lung cancer mortality by 20% in the US National Lung Screening Trial. Here, we present the Yorkshire Lung Screening Trial (YLST), which will address key questions of relevance...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-09-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/10/9/e037075.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556209110351872 |
|---|---|
| author | Richard D Neal Kevin Franks David Torgerson Rachael L Murray David R Baldwin Michael Darby Henrik Moller Richard Booton Una MacLeod Sam M Janes Samantha L Quaife Sebastian Hinde Matthew EJ Callister Suzanne Rogerson Rhian Gabe Mark Sculpher Philip AJ Crosbie Irene Simmonds Martyn Kennedy Nazia Ahmed Ann Cochrane Mike Messenger Puvanendran Tharmanathan |
| author_facet | Richard D Neal Kevin Franks David Torgerson Rachael L Murray David R Baldwin Michael Darby Henrik Moller Richard Booton Una MacLeod Sam M Janes Samantha L Quaife Sebastian Hinde Matthew EJ Callister Suzanne Rogerson Rhian Gabe Mark Sculpher Philip AJ Crosbie Irene Simmonds Martyn Kennedy Nazia Ahmed Ann Cochrane Mike Messenger Puvanendran Tharmanathan |
| author_sort | Richard D Neal |
| collection | DOAJ |
| description | Introduction Lung cancer is the world’s leading cause of cancer death. Low-dose computed tomography (LDCT) screening reduced lung cancer mortality by 20% in the US National Lung Screening Trial. Here, we present the Yorkshire Lung Screening Trial (YLST), which will address key questions of relevance for screening implementation.Methods and analysis Using a single-consent Zelen’s design, ever-smokers aged 55–80 years registered with a general practice in Leeds will be randomised (1:1) to invitation to a telephone-based risk-assessment for a Lung Health Check or to usual care. The anticipated number randomised by household is 62 980 individuals. Responders at high risk will be invited for LDCT scanning for lung cancer on a mobile van in the community. There will be two rounds of screening at an interval of 2 years. Primary objectives are (1) measure participation rates, (2) compare the performance of PLCOM2012 (threshold ≥1.51%), Liverpool Lung Project (V.2) (threshold ≥5%) and US Preventive Services Task Force eligibility criteria for screening population selection and (3) assess lung cancer outcomes in the intervention and usual care arms. Secondary evaluations include health economics, quality of life, smoking rates according to intervention arm, screening programme performance with ancillary biomarker and smoking cessation studies.Ethics and dissemination The study has been approved by the Greater Manchester West research ethics committee (18-NW-0012) and the Health Research Authority following review by the Confidentiality Advisory Group. The results will be disseminated through publication in peer-reviewed scientific journals, presentation at conferences and on the YLST website.Trial registration numbers ISRCTN42704678 and NCT03750110. |
| format | Article |
| id | doaj-art-141871bf552c45debd3c2f5f5adaf27c |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2020-09-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-141871bf552c45debd3c2f5f5adaf27c2025-01-07T11:35:12ZengBMJ Publishing GroupBMJ Open2044-60552020-09-0110910.1136/bmjopen-2020-037075Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at riskRichard D Neal0Kevin Franks1David Torgerson2Rachael L Murray3David R Baldwin4Michael Darby5Henrik Moller6Richard Booton7Una MacLeod8Sam M Janes9Samantha L Quaife10Sebastian Hinde11Matthew EJ Callister12Suzanne Rogerson13Rhian Gabe14Mark Sculpher15Philip AJ Crosbie16Irene Simmonds17Martyn Kennedy18Nazia Ahmed19Ann Cochrane20Mike Messenger21Puvanendran Tharmanathan2218 North Wales Centre for Primary Care Research, Bangor University, Wrexham, UKLeeds Cancer Centre, St James`s Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UKYork Clinical Trials Unit, The University of York, York, UKAcademic Unit of Lifespan and Population Health, University of Nottingham, Nottingham, UKRespiratory Medicine Unit, David Evans Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK3 Department of Radiology, North Bristol NHS Trust, Bristol, UKDanish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark1 Manchester Thoracic Oncology Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UKUniversity of Hull, Hull, UKLungs for Living Research Centre, UCL Respiratory, University College London, London, UK1 Queen Mary University of London, London, UKCentre for Health Economics, University of York, Heslington, York, UKDepartment of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK3 Department of Research and Innovation, Leeds Teaching Hospitals NHS Trust, Leeds, UK1 Wolfson Institute of Population Health, Queen Mary University, London, UKCentre for Health Economics, University of York, York, UKDivision of Infection, Immunity and Respiratory Medicine, The University of Manchester, Manchester, UK2 Leeds Institute of Health Sciences, University of Leeds, Leeds, UKLeeds Teaching Hospitals NHS Trust, Leeds, UKLeeds Institute of Health Sciences, University of Leeds, Leeds, UK1 Department of Health Sciences, University of York, York, UKUniversity of Leeds, Leeds, UKYork Trials Unit, Department of Health Sciences, University of York, York, UKIntroduction Lung cancer is the world’s leading cause of cancer death. Low-dose computed tomography (LDCT) screening reduced lung cancer mortality by 20% in the US National Lung Screening Trial. Here, we present the Yorkshire Lung Screening Trial (YLST), which will address key questions of relevance for screening implementation.Methods and analysis Using a single-consent Zelen’s design, ever-smokers aged 55–80 years registered with a general practice in Leeds will be randomised (1:1) to invitation to a telephone-based risk-assessment for a Lung Health Check or to usual care. The anticipated number randomised by household is 62 980 individuals. Responders at high risk will be invited for LDCT scanning for lung cancer on a mobile van in the community. There will be two rounds of screening at an interval of 2 years. Primary objectives are (1) measure participation rates, (2) compare the performance of PLCOM2012 (threshold ≥1.51%), Liverpool Lung Project (V.2) (threshold ≥5%) and US Preventive Services Task Force eligibility criteria for screening population selection and (3) assess lung cancer outcomes in the intervention and usual care arms. Secondary evaluations include health economics, quality of life, smoking rates according to intervention arm, screening programme performance with ancillary biomarker and smoking cessation studies.Ethics and dissemination The study has been approved by the Greater Manchester West research ethics committee (18-NW-0012) and the Health Research Authority following review by the Confidentiality Advisory Group. The results will be disseminated through publication in peer-reviewed scientific journals, presentation at conferences and on the YLST website.Trial registration numbers ISRCTN42704678 and NCT03750110.https://bmjopen.bmj.com/content/10/9/e037075.full |
| spellingShingle | Richard D Neal Kevin Franks David Torgerson Rachael L Murray David R Baldwin Michael Darby Henrik Moller Richard Booton Una MacLeod Sam M Janes Samantha L Quaife Sebastian Hinde Matthew EJ Callister Suzanne Rogerson Rhian Gabe Mark Sculpher Philip AJ Crosbie Irene Simmonds Martyn Kennedy Nazia Ahmed Ann Cochrane Mike Messenger Puvanendran Tharmanathan Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk BMJ Open |
| title | Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk |
| title_full | Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk |
| title_fullStr | Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk |
| title_full_unstemmed | Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk |
| title_short | Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk |
| title_sort | yorkshire lung screening trial ylst protocol for a randomised controlled trial to evaluate invitation to community based low dose ct screening for lung cancer versus usual care in a targeted population at risk |
| url | https://bmjopen.bmj.com/content/10/9/e037075.full |
| work_keys_str_mv | AT richarddneal yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT kevinfranks yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT davidtorgerson yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT rachaellmurray yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT davidrbaldwin yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT michaeldarby yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT henrikmoller yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT richardbooton yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT unamacleod yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT sammjanes yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT samanthalquaife yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT sebastianhinde yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT matthewejcallister yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT suzannerogerson yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT rhiangabe yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT marksculpher yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT philipajcrosbie yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT irenesimmonds yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT martynkennedy yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT naziaahmed yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT anncochrane yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT mikemessenger yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk AT puvanendrantharmanathan yorkshirelungscreeningtrialylstprotocolforarandomisedcontrolledtrialtoevaluateinvitationtocommunitybasedlowdosectscreeningforlungcancerversususualcareinatargetedpopulationatrisk |